Why new cancer drugs are such a disappointment
The majority of new cancer drugs appear to be no better than their predecessors, research suggests.
Most have entered the market without clear evidence that they improve patient survival or quality of life, according to UK policy experts.
Even where drugs did show survival gains over existing treatments, these were often marginal, their results show.
The researchers found that more than half were approved on the basis of surrogate measures that do not always reliably predict whether a patient will live longer or feel better, raising serious questions about the current standards of drug